52nd week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130343942 | ROTARY COMPRESSOR - A rotary compressor ( | 2013-12-26 |
20130343943 | METHODS FOR PREPARING METALLURGICAL POWDER COMPOSITIONS AND COMPACTED ARTICLES MADE FROM THE SAME - Provided are methods of preparing high density compacted components that increase that lubricity of metallurgical powder compositions while reducing the overall organic content of the compacted component. Method of preparing high density compacted components having a high density include the steps of providing a metallurgical powder composition having particles at least partially coated with a metal phosphate layer, and compacting the metallurgical powder composition in the die at a pressure of at least about 5 tsi. The metallurgical powder composition comprises a base-metal powder, optional alloying powders, and a particulate internal lubricant. The metal phosphate at least partially coats the base-metal powder, the optional alloying powder, or both. The metal phosphate coating increases the lubricity of metallurgical powders without the need for large quantities of organic material, e.g., lubricants and binders. | 2013-12-26 |
20130343944 | MATERIAL WITH HIGH RESISTANCE TO WEAR - Material and method for the production of material with isotropic, mechanical properties and improved wear resistance and high hardness potential. Method includes producing in a powder metallurgical (PM) method a slug or ingot from a material of ledeburite tool steel alloy, and subjecting one of the slug or ingot or a semi-finished product produced from the slug or ingot to full annealing at a temperature of over 1100° C., but at least 10° C. below the fusing temperature of the lowest melting structure phase with a duration of over 12 hrs. In this manner, an average carbide phase size of the material is increased by at least 65%, a surface shape of the material is rounded and a matrix is homogenized. Method further includes subsequently processing the material into thermally tempered tools with high wear resistance occurs or into parts to which abrasive stress is applied. | 2013-12-26 |
20130343945 | TITANIUM BORIDE - A titanium metal or a titanium alloy having submicron titanium boride substantially uniformly dispersed therein and a method of making same is disclosed. Ti power of Ti alloy powder has dispersed within the particles forming the powder titanum boride which is other than whisker-shaped or spherical substantially uniformly dispersed therein. | 2013-12-26 |
20130343946 | METHOD AND SYSTEM FOR MANUFACTURING SINTERED RARE-EARTH MAGNET HAVING MAGNETIC ANISOTROPY - A method for manufacturing a sintered rare-earth magnet having a magnetic anisotropy, in which a very active powder having a small grain size can be safely used in a low-oxidized state. A fine powder as a material of the sintered rare-earth magnet having a magnetic anisotropy is loaded into a mold until its density reaches a predetermined level. Then, in a magnetic orientation section, the fine powder is oriented by a pulsed magnetic field. Subsequently, the fine powder is not compressed but immediately sintered in a sintering furnace. A multi-cavity mold for manufacturing a sintered rare-earth magnet having an industrially important shape, such as a plate magnet or an arched plate magnet, may be used. | 2013-12-26 |
20130343947 | METHOD AND DEVICE FOR PROCESS MONITORING - Disclosed is a method for monitoring a generative production process in real time, wherein a component is at least optically detected and the installation space is thermally detected when applying a layer, as well as a device for carrying out said method. | 2013-12-26 |
20130343948 | DUPLEX STAINLESS STEEL SUPERIOR IN CORROSION RESISTANCE OF WELD - A nitrogen-rich two-phase stainless steel that has corrosion resistance equal to that of standard type of two-phase stainless steel and is not susceptible to corrosion in a welding heat-affected part, wherein the austenite phase area ratio is 40-70%, the PI value expressed by formula (1) is 30-38, the NI value expressed by formula (2) is 100-140, and the γpre expressed by formula (3) is 1350-1450. (1) PI=Cr+3.3Mo+16N (2) NI=(Cr+Mo)/N | 2013-12-26 |
20130343949 | Steel Material for Machine Structural Use Reduced in Thermal Deformation - Disclosed is a steel material with small heat treatment deformation, comprising a machine structural steel used for components for power transmission, such as gears and shafts used in automobiles, industrial machines, and the like. The steel material comprises in mass %: C: 0.16 to 0.35%; Si: 0.10 to 1.50%; Mn: 0.10 to 1.20%; P: 0 to 0.030%; S: 0 to 0.030%; Cr: 1.3 to 2.5%; Cu: 0 to 0.30%; Al: 0.008 to 0.800%; O: 0 to 0.0030%; N: 0.0020 to 0.0300%; Ni: 0 to 3.00%; Mo: 0 to 0.50%; Ti: 0 to 0.200%; Nb: 0 to 0.20%; and the balance Fe and unavoidable impurities. | 2013-12-26 |
20130343950 | NANOWIRE PREPARATION METHODS, COMPOSITIONS, AND ARTICLES - Methods of producing metal nanowires employing tubular continuous-flow reactors and their products are described and claimed. Such methods can provide superior nanowire uniformity without agglomeration. Such nanowires are useful for electronic applications. | 2013-12-26 |
20130343951 | METHOD FOR MANUFACTURING A GASEOUS MIXTURE FOR TREATING POLLUTED ATMOSPHERES, DEVICE FOR IMPLEMENTING SAME, AND USE THEREOF - The present disclosure relates to the field of treating atmospheres that are laden with substances that are nauseating and/or detrimental to human or animal health, specifically to the field of deodorising, perfuming, and/or purifying air at industrial or private sites. For this purpose, there is disclosed a method for enriching, preferably saturating, ordinary atmospheric air with active substances present in the gas phase, to a device for implementing the method, and to the use of the method for the treatment of polluted atmospheres. The method is especially characterized in that it advantageously includes a step of reinjecting a portion of the enriched gaseous mixture (MG) into an enrichment or saturation chamber ( | 2013-12-26 |
20130343952 | ANTI-MICROBIAL GAS APPARATUS AND METHOD - An apparatus and method administering nitric oxide at very high concentrations to healthy skin, tools, implements, support surfaces, and sterile fields to provide sterilization. The apparatus and method providing sterilization in a dry environment lacking the common undesirable effects of anti-microbial soaps and antiseptics. | 2013-12-26 |
20130343953 | TREATMENT OF FLUID-BORNE CANCER CELLS - Provided are devices, device systems, and methods to intercept and kill fluid borne cancer cells to slow or prevent metastases. | 2013-12-26 |
20130343954 | COMPACT INTEGRATED BLOOD PUMP OXYGENATOR OR GAS TRANSFER DEVICE WITH HYDROGEL IMPELLER PACKING MATERIAL AND ROLLOVER IMPELLER OUTLET - An integrated blood pump oxygenator comprises an an impeller housing supporting an impeller; with an annular hydrogel impeller packing material adjacent the bearings and around the shaft of the impeller. The oxygenator including a rollover outlet in the form of an annular chamber extending around a center pump housing member; and further including an annular chamber within an annular array of hollow fiber membranes in fluid communication with the annular chamber extending from the impeller around the center pump housing; wherein the annular chamber provides substantially perpendicular radial outward cross flow across the membranes. | 2013-12-26 |
20130343955 | Integrated Cartridge Housings For Sample Analysis - The invention relates to a cartridge housing for forming a cartridge capable of measuring an analyte or property of a liquid sample. The housing including a top portion having a first substantially rigid zone and a substantially flexible zone, a bottom portion separate from the top portion including a second substantially rigid zone, and at least one sensor recess containing a sensor. The top portion and the bottom portion are bonded to form the cartridge having a conduit over at least a portion of the sensor. The invention also relates to methods for forming such cartridges and to various features of such cartridges. | 2013-12-26 |
20130343956 | INTEGRATED HYDROCRACKING AND FLUIDIZED CATALYTIC CRACKING SYSTEM - A system and method of cracking hydrocarbon feedstocks is provided that allows for significant flexibility in terms of the desired product yield. An integrated process includes introducing the feedstock and hydrogen into a first hydrocracking reaction zone containing a first hydrocracking catalyst to produce a first zone effluent. The first zone effluent is passed to a fractionating zone to produce at least a low boiling fraction and a high boiling fraction, and optionally one or more intermediate fractions. The bottoms fraction is conveyed to a fluidized catalytic cracking reaction and separation zone, from which olefins and gasoline are recovered. At least a portion of remaining cycle oil is passed from the fluidized catalytic cracking reaction and separation zone to a second hydrocracking reaction zone containing a second hydrocracking catalyst to produce a second stage effluent. At least a portion of the second stage effluent is recycled to the fractionating zone and/or the first hydrocracking reaction zone. | 2013-12-26 |
20130343957 | CRACKING SYSTEM INTEGRATING HYDROCRACKING AND FLUIDIZED CATALYTIC CRACKING - A system and method of cracking hydrocarbon feedstocks is provided that allows for significant flexibility in terms of the desired product yield. An integrated process includes introducing the feedstock and hydrogen into a first hydrocracking reaction zone containing a first hydrocracking catalyst to produce a first zone effluent. The first zone effluent and optionally additional hydrogen are passed to a second hydrocracking reaction zone containing a second hydrocracking catalyst to produce a second zone effluent. The second zone effluent is conveyed to a fractionating zone to at least a low boiling fraction and a high boiling fraction, and optionally one or more intermediate fractions. The bottoms fraction is passed to a fluidized catalytic cracking reaction and separation zone, from which olefins and gasoline are recovered. At least a portion of remaining cycle oil is passed from the fluidized catalytic cracking reaction and separation zone to the first and/or second hydrocracking reaction zone. | 2013-12-26 |
20130343958 | FUEL SYSTEM - A fuel system ( | 2013-12-26 |
20130343959 | COMMON RAIL REDUCTANT INJECTION SYSTEM - An exhaust system including a selective catalytic reduction (SCR) component and an oxidation catalyst component. The exhaust system also includes an exhaust treatment fluid injection system for dispersing an exhaust treatment fluid into an exhaust stream at a location adjacent either the SCR component or the oxidation catalyst component, wherein the exhaust treatment fluid injection device includes a common rail that provides the exhaust treatment fluid under pressure to a plurality of injectors that dose the exhaust treatment fluid into the exhaust stream. The exhaust treatment fluid injection device also includes a return rail for returning unused exhaust treatment fluid to the fluid source. | 2013-12-26 |
20130343960 | HYDROCARBON FEED FLEXIBLE HIGH PRESSURE NITRATION PLANT DESIGN - Disclosed is an apparatus for synthesizing nitroalkanes by reaction of a hydrocarbon feedstock with aqueous nitric acid. The apparatus may be designed such that it can synthesize more than one nitroalkane using the same equipment. | 2013-12-26 |
20130343961 | Apparatus for Retaining Solid Material in a Radial Flow Reactor and Method of Making - An apparatus for use in radial flow reactors is presented. The apparatus includes a first partition and a second partition with support members coupled therebetween. The first partition include a first opening and a second opening to allow the passage of fluid therethrough. A baffle extends into a flow channel formed by adjacent support members to obstruct an upper or lower portion of the first opening to interrupt a portion of the fluid flow therethrough. | 2013-12-26 |
20130343962 | OXIDATION METHOD AND REACTOR - A method and apparatus for increasing the concentration of oxygen in the reaction medium present in the oxidation reactor. A volume of aqueous medium from the oxidation reactor is removed and pressurized and oxygen is added to it. The oxygen-rich volume of aqueous medium is then reintroduced into the oxidation reactor at an increased pressure to ensure adequate mixing with the aqueous medium having a lower content of oxygen. | 2013-12-26 |
20130343963 | TEST SENSOR PACKAGE - A fluid sensor comprises a formed plastic body and a reagent. The body has a top face with an integral first surface. The body also has a bottom face opposed to the first surface and a sidewall that extends from the periphery of the top face. The first surface is adapted to accept a fluid sample. The reagent is disposed on the integral first surface and causes a color change detectable on the bottom face when the reagent reacts with an analyte in the fluid sample. | 2013-12-26 |
20130343964 | TEST ELEMENTS AND METHODS OF PRODUCING THE SAME FOR STUDYING A BODY FLUID SAMPLE - Disclosed herein are methods of producing a test element for studying a body fluid sample. In the methods, a detection layer is covered with a polymeric spreading layer and applied to a support. The spreading layer can be produced by being sprayed onto the detection layer such that the spreading layer has a thickness of at most about 20 μm. Also disclosed are test elements produced by the methods, as well as tape cassettes incorporating such test elements. | 2013-12-26 |
20130343965 | CONDENSED GEOMETRY NOZZLE FOR FLOW CYTOMETRY - Disclosed is a nozzle assembly that is compact in size and that uses plastic tubing as an injection needle. Standard plastic fittings are utilized, which are inexpensive and widely available. The nozzle assembly has a simple construction and can be easily assembled and disassembled in a few minutes by a user. Cleaning and/or replacement of parts is inexpensive. Plastic tubing can be used as an injection needle that has superior qualities over commonly used stainless steel injection needles. Flexure of the injection needle tubing is prevented because of the compact size of the nozzle cavity. | 2013-12-26 |
20130343966 | Microfluidic Device for the Manipulation of Particles - A microfluidic device for isolating particles of at least one given type of a sample; the device is designed to be connected to an apparatus through a plurality of electrical connectors and comprises a system of microfluidic channels and a flash memory, which contains information on the structure (arrangement and geometry of the various components) of the system of microfluidic channels, a map of non-functioning parts of the device, the maximum number of uses and the maximum time of use of the device; the memory has portions allocated for storing the number of times and the time of use of the device. | 2013-12-26 |
20130343967 | DEVICE FOR CENTRIFUGATION AND FURTHER PROCESSING OF TISSUE ASPIRATES IN CLOSED SYSTEM - The device enables to put the patients own bone marrow derived stem cells on a lyophilized bone allograft covered by human albumin, after a short separation by centrifugation. The cell concentrator comprises a closed housing ( | 2013-12-26 |
20130343968 | PACKAGING STRUCTURE - The present invention provides a packaging structure, which includes a plurality of dry analytical elements that are stacked on top of one another in a thickness direction; a packaging bag into which the dry analytical elements are placed and that is separable in two along a planar direction of the dry analytical elements; and protective sheets that are placed in between the dry analytical elements and that are each fixed, at one end, to one side of the packaging bag that is separable in two. | 2013-12-26 |
20130343969 | Particulate Materials for Uranium Extraction and Related Processes - Extraction method for recovering metals. Phosphoric acid is contacted with an extractant suspension of solid particulate material comprising a para- or ferromagnetic material core surrounded by an outer shell of a chelating polymer whereby a metal is the solution is adsorbed on the chelating polymer, thereby removing it from the phosphoric acid solution. The metal-containing solid particulate material is magnetically separated from the solution and the metal is stripped from the solid particulate material for reuse. | 2013-12-26 |
20130343970 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS - The invention provides methods and compositions for inhibiting the accumulation of DSP scale in the liquor circuit of Bayer process equipment. The method includes adding one or more particular silane based small molecules to the liquor fluid circuit. These scale inhibitors reduce DSP scale formation and thereby increase fluid throughput, increase the amount of time Bayer process equipment can be operational and reduce the need for expensive and dangerous acid washes of Bayer process equipment. As a result, the invention provides a significant reduction in the total cost of operating a Bayer process. | 2013-12-26 |
20130343971 | METHOD FOR CO-PRODUCING ALUMINA AND ACTIVATED CALCIUM SILICATE FROM HIGH-ALUMINA FLY ASH - A method for co-producing alumina and activated calcium silicate from high-alumina fly ash, comprising the steps that: high-alumina fly ash reacts with sodium hydroxide solution to obtain desiliconized solution and desiliconized fly ash; lime cream is added to the desiliconized solution to obtain activated calcium silicate; limestone and sodium carbonate solution are added to the desiliconized fly ash to blend raw slurry, the raw slurry is baked into clinker, and sodium aluminate crude solution is obtained from dissolution of the clinker; the sodium aluminate crude solution is subjected to the processes of first-stage deep desiliconization, second-stage deep desiliconization, carbonization decomposition, seed precipitation and etc to obtain alumina. According to the invention, less material flow and small amount of slag formation are achieved, the energy consumption, material consumption and production cost are low; the extraction rate of alumina is high, and meanwhile, activated calcium silicate with high added value is co-produced. | 2013-12-26 |
20130343972 | METHOD FOR TREATING LIQUID EFFLUENTS AND RECOVERING METALS - A method for treating liquid effluents and recovering metals is described, which comprises the steps of: a) liquid effluent equalization; b) sulphide addition and precipitation of metals in the form of metal sulphides; c) solid/liquid separation of the metal sulphides produced in step (b) and formation of a metal-free liquid phase; d) addition of a 50 to 250 g/L amine solution to the liquid phase precipitating magnesium in the form of magnesium hydroxide (Mg(OH)2); and e) recovery of amine by stripping and rectification. | 2013-12-26 |
20130343973 | ABSORBENT FOR OPTICS AND ELECTRICAL COMPONENTS - The invention general provides a method of absorbing gases from manufactured articles comprising providing a gas absorbent in gaseous contact with the manufactured article wherein the gas absorber comprises activated carbon, molecular sieve, and alkaline salt. | 2013-12-26 |
20130343974 | ACID GAS ABSORBENT, ACID GAS REMOVAL METHOD, AND ACID GAS REMOVAL DEVICE - An acid gas absorbent comprising at least one type of diamine compound represented by the following general formula (1), | 2013-12-26 |
20130343975 | AMMONIA OXIDATION CATALYST HAVING LOW N2O BY-PRODUCT FORMATION - The present invention relates to a catalytic composition comprising a noble metal on an acidic tungsten-containing mixed oxide, a method for producing the catalytic composition and the use of the catalytic composition as oxidation catalyst. The invention further relates to a catalyst shaped body, which has the catalytic composition on a support, a washcoat containing the catalytic composition according to the invention and the use of the washcoat to produce a coated catalyst shaped body. | 2013-12-26 |
20130343976 | CARBON DIOXIDE RECOVERY DEVICE AND CARBON DIOXIDE RECOVERY METHOD - According to one embodiment, a carbon dioxide recovery device includes an absorption tower configured to cause carbon dioxide-containing gas to come in contact with absorbing solution and to generate rich solution absorbing the carbon dioxide, a regeneration tower configured to heat the rich solution, to disperse steam containing the carbon dioxide, and to generate lean solution from which the carbon dioxide is removed, a heat exchanging device configured to exchange heat between the lean solution and the rich solution, to supply the rich solution after the heat exchange to the regeneration tower, and to supply the lean solution after the heat exchange to the absorption tower, and a cooling device configured to cool a part of the rich solution discharged from a first place of the absorption tower and to supply the cooled rich solution to a second place higher than the first place of the absorption tower. | 2013-12-26 |
20130343977 | CONTINUOUS DIFFUSION DENUDING WITH MOVING DENUDING SURFACE - A duct can be configured to receive a denuding gas flow. A solid denuding surface that is connected to a drive system can be configured to move the solid denuding surface within the duct while the solid denuding surface is continuously concentrating one or more gas-phase species from the denuding gas flow on the denuding surface. Also, a denuding gas flow can be passed along a denuding surface to concentrate one or more gas phase species from the denuding gas flow onto the denuding surface with a diffusion denuding action. The denuding surface can be moved while continuing to concentrate the one or more gas phase species from the denuding gas flow onto the denuding surface. | 2013-12-26 |
20130343978 | SOUR GAS AND ACID NATURAL GAS SEPARATION MEMBRANE PROCESS BY PRE REMOVAL OF DISSOLVED ELEMENTAL SULFUR FOR PLUGGING PREVENTION - Methods for removing sulfur from a gas stream prior to sending the gas stream to a gas separation membrane system are provided. Two schemes are available. When the sulfur content is high or flow is relatively high, a scheme including two columns where one tower is regenerated if the sulfur concentration exceeds a preset value can be used. When the sulfur content is low or flow is relatively low, a scheme including one column and an absorption bed. | 2013-12-26 |
20130343979 | HIGHLY EFFICIENT METHOD FOR PRODUCING CERAMIC MICROPARTICLES - Provided is a more suitable method for producing ceramic microparticles. The present invention uses at least two types of fluids to be processed; at least one of the fluids to be processed is a fluid containing a ceramic starting material liquid that mixes and/or dissolves a ceramic starting material in a basic solvent; of the fluids aside from the ceramic starting material liquid, at least one of the fluids to be processed is a fluid containing a solvent for precipitating ceramic microparticles; and ceramic microparticles are precipitated by mixing the fluid containing the ceramic starting material liquid and the fluid containing the solvent for precipitating ceramic microparticles within a thin film fluid formed between at least two surfaces ( | 2013-12-26 |
20130343980 | METHOD FOR PREPARING A COMPOSITION INCLUDING SYNTHETIC INORGANIC PARTICLES - A method for preparing a composition including synthetic mineral particles, in which: a hydrogel that is a precursor of the synthetic mineral particles is prepared, and the hydrogel is subjected to a hydrothermal treatment, characterized in that at least one step of the hydrothermal treatment is carried out with the addition of at least one carboxylate salt to the treatment medium, the carboxylate salt having the formula R—COOM′, where M′ denotes a metal selected from the group consisting of Na and K, and R is selected from H and the alkyl groups that include fewer than 10 carbon atoms. | 2013-12-26 |
20130343981 | EXTRACTION AND SEQUESTRATION OF CARBON DIOXIDE - The present disclosure provides a method and apparatus for extracting carbon dioxide (CO | 2013-12-26 |
20130343982 | PROCESS FOR MAKING MULTI-WALLED CARBON NANOTUBES AND MULTI-WALLED CARBON NANOTUBES FORMED THEREFROM - A process for making multi-walled carbon nanotubes includes contacting a hydrocarbon-containing gas with an electron beam-treated fly ash catalyst. The electron beam-treated fly ash catalyst contains a total amount of iron oxide and vanadium oxide of up to 5 wt. %. The multi-walled carbon nanotubes may be formed in a low pressure chemical vapor deposition apparatus. | 2013-12-26 |
20130343983 | LITHIUM-TITANIUM COMPLEX OXIDE AND MANUFACTURING METHOD THEREOF, AND BATTERY ELECTRODE USING SAME - A lithium-titanium complex oxide whose total water generation amount and total carbon dioxide generation amount measured by thermal decomposition GC-MS are preferably 1500 wt ppm or less and 2000 wt ppm or less, respectively, is obtained by subjecting a mixture of titanium compound and lithium compound to a heat treatment at 600° C. or above, cooling the obtained reaction product to 50° C. or below, and then subjecting the cooled reaction product to a reheat treatment involving heating to the maximum temperature of 300 to 700° C. and then cooling, wherein the dew point of the ambience of the reheat treatment is controlled at −30° C. or below at a temperature of 200° C. or above. | 2013-12-26 |
20130343984 | DEVICE FOR MAKING NANO-SCALE PARTICLES OF TITANIUM DIOXIDE AND METHOD OF MAKING NANO-SCALE PARTICLES OF TITANIUM DIOXIDE USING THE DEVICE - A device for making nano-scale particles of titanium dioxide includes a vacuum chamber; an evaporator, a gas supplier, a vacuum pump assembly, and a product collecting device. The evaporator is mounted in the vacuum chamber. The gas supplier communicates with the vacuum chamber. The vacuum pump assembly communicates with the vacuum chamber. The product collecting device includes a pump, a guide pipe connected with the pump, and a powder collector communicating with the guide pipe. The pump communicates with the vacuum chamber. The guide pipe is inserted in the powder collector, the powder collector is filled with organic solvents. A method of making nano-scale particles of titanium dioxide using the device is also provided. | 2013-12-26 |
20130343985 | CATALYST-CONTAINING REACTOR SYSTEM AND ASSOCIATED METHODS - In accordance with one or more embodiments, a tubular catalyst-containing reactor system is provided. The system includes a housing and a vaporizer unit in the housing comprising a helically wound tubular assembly for receiving and at least partially vaporizing a liquid chemical reactant stream. A reformer unit in the housing receives a vaporized chemical reactant stream from the vaporizer unit. The reformer unit comprises a helically wound tubular assembly connected to and positioned coaxially relative to the helically wound tubular assembly of the vaporizer unit. The helically wound tubular assembly of the reformer unit contains a catalyst for catalyzing formation of gas product stream from the vaporized chemical reactant stream. A burner unit heats the vaporizer unit and the reformer unit. The burner unit receives a fuel stream and an air stream and produces a flame generally inside the helically wound tubular assemblies of the vaporizer unit and the reformer unit. | 2013-12-26 |
20130343986 | METHOD FOR PRODUCING MTW-TYPE ZEOLITE - Provided is a method for producing an MTW-type zeolite. The reaction mixture contains a silica source, an alumina source, an alkali source, and water is reacted with a seed crystal of a zeolite to produce an MTW-type zeolite. The reaction mixture has a composition, which makes a synthesized zeolite contain an MFI-type zeolite when the zeolite is synthesized solely from the reaction mixture, is used. As the seed crystal, a beta-type zeolite which has a ratio of SiO | 2013-12-26 |
20130343987 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 2013-12-26 |
20130343988 | Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer - The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer. | 2013-12-26 |
20130343989 | Methods and Compositions Related to Internalizing RGD Peptides - Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing αv integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing αv integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing αv integrins. | 2013-12-26 |
20130343990 | RADIOLABELLED OCTREOTATE ANALOGUES AS PET TRACERS - Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s). | 2013-12-26 |
20130343991 | ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER - Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans. | 2013-12-26 |
20130343992 | RADIOLABELED PDE10A LIGANDS - Compounds of formula (I) are disclosed | 2013-12-26 |
20130343993 | RADIOLABELED 5-HT6 LIGANDS - Compounds of formula (I) are disclosed | 2013-12-26 |
20130343994 | Cholinesterase Inhibitors - The invention provides compounds that inhibit cholinesterases, such as acetylcholinesterase and butyrylcholinesterase. Such compounds are useful to prevent or treat exposure of a patient (e.g., a human) to an organophosphoric nerve agent (e.g., sarin and VX) or to treat a patient suffering from a neurodegenerative disorder such as Alzheimer's Disease or Lewy Body Dementia. The compounds are further useful as diagnostic tools for use in medical or research radiography (e.g., positron emission tomography) when synthesized with a radionuclide (e.g., [18F]. Synthetic schemes to produce such compounds are also provided. | 2013-12-26 |
20130343995 | EFFICIENT SYNTHESIS OF ETHYLENEDICYSTEINE-SUGAR CONJUGATES FOR IMAGING AND THERAPY - Novel methods of synthesis of ethylenedicysteine-sugar conjugates and therapeutic and diagnostic applications of such conjugates are disclosed. Methods of synthesizing these conjugates in high purity are also presented as using starting materials such as thiazolidine carboxylic acid. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these conjugates prepared herein, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia. | 2013-12-26 |
20130343996 | GRAPHITE-COATED MAGNETIC NANOPARTICLES - The present invention relates to graphite-coated magnetic nanoparticles, methods for the synthesis of graphite-coated magnetic nanoparticles, and methods of using graphite-coated magnetic nanoparticles for targeted delivery of siRNA-based therapy, as multimodal imaging probes and for hyperthermia cancer treatment. | 2013-12-26 |
20130343997 | Metal Coating of Rare Earth Nano-Phosphors and Uses Thereof - Core-shell nanoparticles comprises a phosphorescent core and metal shell comprising at least two metals The phosphorescent core may comprise an up converting phosphor. The phosphorescent core may comprise a trivalent rare earth cation. The phosphorescent core further may comprise a monovalent alkali metal. The phosphorescent core may optionally comprises a second and also optionally a third trivalent rare earth cation. | 2013-12-26 |
20130343998 | Control and Characterization of Memory Function - Provided herein are devices and methods for reversibly controlling memory function in living non-human animals. Some variations of methods for affecting memory function comprise temporarily inhibiting neurons of the hippocampus (e.g., neurons of the dorsal CA1 field of the hippocampus) during the acquisition or retrieval of a memory. Alternatively or additionally, methods for reversibly affecting memory function comprise inhibiting neurons of the amygdala (e.g. basolateral amygdala) and/or neurons of the cingulate cortex (e.g., anterior cingulated cortex). Methods for disrupting the formation and recall of memories by inhibiting excitatory neurons expressing light-activated proteins are disclosed herein. One or more methods for reversibly affecting memory function described herein can be used to evaluate the effectiveness of pharmacological agents in treating PTSD and/or various memory disorders. | 2013-12-26 |
20130343999 | COMPOSITIONS AND METHODS FOR PRODUCING EMULSIONS FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES AND OTHER APPLICATIONS - The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substrate. | 2013-12-26 |
20130344000 | TREATMENT OF COGNITIVE IMPAIRMENT IN A SUBJECT WITH A NEUROLOGICAL AUTOIMMUNE DISEASE - Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment. | 2013-12-26 |
20130344001 | INDOCYANINE GREEN-CONTAINING PARTICLES, PHOTOACOUSTIC-IMAGING CONTRAST AGENT INCLUDING THE SAME, AND METHOD FOR PRODUCING THE INDOCYANINE GREEN-CONTAINING PARTICLES - Indocyanine green-containing particles each include a metal oxide particle or a metal particle and an aggregate of indocyanine green. The aggregate of indocyanine green has a relative maximum absorbance at 880 nm or more and 910 nm or less. | 2013-12-26 |
20130344002 | FOLATE TARGETED ENHANCED TUMOR AND FOLATE RECEPTOR POSITIVE TISSUE OPTICAL IMAGING TECHNOLOGY - A method of differentiating tumors from healthy cells in tissue is disclosed. The method includes the steps of providing a marker-folate conjugate, placing the marker-folate conjugate in contact with the tissue and viewing the tissue. | 2013-12-26 |
20130344003 | IMMUNO-THERAPY FOR CANCER TREATMENT USING IRON OXIDE NANOPARTICLES - An immuno-therapy for treatment of a tumor is provided. An effective dose of a composition containing a low dose of superparamagnetic iron oxide nanoparticle is administered to a tumor. Once the composition has been administered, it is recommended to avoid any means that would cause direct cytotoxic effects to the cancer cells and to normal/healthy tissue. The combination of composition-administered cancer cells with the avoidance of direct cytotoxic effects has been shown to be successful to inhibit the growth of the cancer cells or result in aptosis of the cancer cells. Additional dose(s) can be administered when it is determined that: (i) the tumor starts to grow and/or (ii) the remaining composition falls below a threshold. The immuno-therapy method is a safe, clinically applicable, ready-to-use theranostic approach for cancer patients who are unable to start chemoradiotherapy in a timely manner, i.e. an effective interim or adjunctive treatment for patients. | 2013-12-26 |
20130344004 | MATRIX METALLOPROTEASE TARGETING NUCLEIC ACIDS - A reporter conjugate for non-invasive detection (e.g., imaging) of matrix metalloprotease (MMP) gene expression in vivo is disclosed. The conjugate includes a targeting nucleic acid linked to a contrast agent, such as a paramagnetic label that can be used with magnetic resonance (MR) imaging. The targeting nucleic acid can be an antisense strand that hybridizes to a portion of a messenger RNA encoded by the gene whose expression is to be imaged. In some embodiments, the contrast agent is a chelated metal such as gadolinium or dysprosium. The invention also features methods to detect MMP gene expression in various tissues, including the brain. | 2013-12-26 |
20130344005 | BOLUS FOR TREATING HYPOCALCAEMIA IN RUMINANTS - The subject of the invention is a veterinary product or a nutrition product intended in particular for the prevention and treatment of hypocalcaemia in ruminant animals. The product is in the form of a bolus comprising calcium carbonate and calcium formate. Advantageously, two of these boluses are concomitantly administered, one being a rapid-release effervescent bolus and the other being a slow-release bolus. | 2013-12-26 |
20130344006 | HAIR TREATMENT COMPOSITIONS - A hair treatment composition comprising an acrylic pressure sensitive adhesive consisting essentially of a random copolymers comprising: i) an acrylic group having a side-chain with at least 4 carbons (eg n-butyl acrylate or 2-ethylhexyl acrylate) and; ii) a short side-chain acrylic such as methyl acrylate; the weight ratio of C | 2013-12-26 |
20130344007 | FRANKINCENSE CHEWING GUM - This disclosure relates to a composition that may include frankincense resin and various combinations of essential oils, which combinations may be effective in promoting weight loss. The present disclosure further relates to a weight loss and satiation composition that may include frankincense resin and a flavorant. In some embodiments, the composition may include a gum base. | 2013-12-26 |
20130344008 | NONCARIOUS MATERIAL AND ANTICARIOUS AGENT CONTAINING RARE SUGAR - To provide a composition for preventing periodontal diseases (prophylactic agent of periodontal diseases), the composition having an excellent cariostatic property, being safe and stable for prolonged use and having less effects on flavor. A non-cariogenic material prepared by blending a rare sugar in the D form as selected from the group consisting of D-psicose, D-sorbose and D-tagatose, a rare sugar in the L form as selected from L-fructose, L-psicose and L-tagatose, or allitol as a rare sugar derivative, singly or in combination. A cariostatic agent comprising D-psicose, D-sorbose, D-tagatose, L-fructose, L-psicose and/or L-tagatose. A cariostatic agent in combination with catechins. | 2013-12-26 |
20130344009 | FOAMING ORAL CARE FORMULATION AND SYSTEM AND METHOD OF FORMING AND USING SAME - Oral care compositions, systems, and methods of using and forming the compositions and systems are disclosed. The composition includes a surfactant and/or a foaming agent to cause the composition to foam prior to administration to an oral cavity. The foaming composition readily and quickly reaches interstitial areas within the oral cavity and at a gum line. In addition, the foaming action makes the composition enjoyable for use by children, which, in turn, encourages compliance with use. | 2013-12-26 |
20130344010 | Oral Health Improving Compositions - The present invention is concerned with microorganisms or fragments thereof as sensorically neutral oral care agents, particularly for prevention of dental calculus, as anti-caries agents and/or anti-oral malodor agents. The invention is furthermore concerned with compositions comprising microorganisms or fragments thereof for reducing mutans Streptococci. Such compositions can be used in oral care compositions, e.g. for caries prophylaxis, or for prophylaxis of dental calculus or oral malodor. They may also or instead be used for prevention or treatment of oral malodor. As the microorganisms and fragments thereof according to the present invention have a very low, unobtrusive smell and taste, they are particularly suited as sensorically neutral agents for preventment of dental calculus, caries, oral biofilm formation and/or for prevention or treatment of oral malodor. The microorganisms and fragments thereof, and also compositions comprising such microorganisms and fragments, can thus advantageously be used in food and feed compositions, particularly in pet foods. Furthermore, the invention is concerned with methods of preparing such microorganisms, fragments, compositions, foods and feeds. | 2013-12-26 |
20130344011 | Reduction Of Tooth Staining Derived From Cationic Antimicrobials - Disclosed are oral care compositions having reduced tooth staining propensity and comprising in a pharmaceutically acceptable carrier, a cationic antimicrobial agent and an anti-stain agent comprising one or more materials from each of at least two of the following chemical groups:
| 2013-12-26 |
20130344012 | NATURAL OIL METATHESIS COMPOSITIONS AND METHODS - A metathesized natural oil composition comprising (i) a mixture olefins and/or esters, or (ii) a metathesized natural oil, is disclosed. The metathesized natural oil composition has a number average molecular weight in the range from about 100 g/mol to about 150,000 g/mol, a weight average molecular weight in the range from about 1,000 g/mol to about 100,000 g/mol, a z-average molecular weight in the range from about 5,000 g/mol to about 1,000,000 g/mol, and a polydispersity index of about 1 to about 20. The metathesized natural oil composition is metathesized at least once. | 2013-12-26 |
20130344013 | Water-in-Oil Emulsified Sunscreen Cosmetic - The present invention provides a water-in-oil emulsified sunscreen cosmetic characteristically comprising the following (a) through (g):
| 2013-12-26 |
20130344014 | THERAPEUTIC VITAMIN D SUN-PROTECTING FORMULATIONS AND METHODS FOR THEIR USE - The present invention concerns topical sun-protecting formulations including therapeutically effective amounts of Vitamin D, including formulations that provide Vitamin D in bioavailable amounts that correspond to decreased natural Vitamin D production resulting from the sun-blocking effects of the formulations and formulations for the prevention and treatment of disorders and disease states associated with vitamin D deficiency and vitamin D insufficiency. | 2013-12-26 |
20130344015 | Aqueous Fluid Photoprotective Compositions Comprising Tertiary-Amine-Terminated Polyamide Polymers - Topically applicable, fluid anti-sun/sunscreen compositions useful for protecting the skin and/or the hair against the damaging effects of ultraviolet radiation, contain:
| 2013-12-26 |
20130344016 | METHOD AND APPARATUS FOR APPLYING SOLID PAINT TO SKIN - An apparatus for applying solid paint to the skin includes a housing having opposite first and second ends, a first quantity of solid paint in a first receptacle, a second quantity of solid paint in a second receptacle, and an actuator for longitudinally shifting the first receptacle relative to the housing. A pusher may be operatively coupled to the actuator and include a threaded shaft and a first receiver configured for removably mounting the first receptacle. The pusher and the first receptacle mounted therein may move longitudinally relative to the housing corresponding to relative rotational movement of the actuator. The first and second receptacles may be removably mounted in the apparatus whereby the receptacles and the quantities of solid paint contained therein may be removed and replaced without the need for tools. The first and second receptacles may be sized and configured so that their positions may be alternated. | 2013-12-26 |
20130344017 | HAIR TREATMENT COMPOSITION - A hair treatment composition comprising: i) an oligosaccharide comprising 3 to 7 sugar units in which the linkage group between the sugar units is an a 1-4 link; and ii) an acrylic pressure sensitive adhesive comprising: i) an acrylic group having a side-chain with at least 4 carbons (eg n-butyl acrylate or 2-ethylhexyl acrylate) and; ii) a short side-chain acrylic such as methyl acrylate. the weight ratio of short side chain acrylic group ii) to the acrylic group i). | 2013-12-26 |
20130344018 | COSMETIC COMPOSITION COMPRISING A PARTICULAR ZINC SALT AND A STARCH - The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one non-nitrogenous zinc salt and at least one starch, in a weight ratio of the amount of starch to the amount of zinc element ranging from 0.01 to 20. Another subject of the invention relates to a process for treating keratin fibres, using such a composition, and to the use of such a composition, preferably in the form of a leave-on care product, for conditioning keratin fibres and for protecting their artificial colour from fading. | 2013-12-26 |
20130344019 | ACRYLIC POLYMER - The present invention relates to acrylic emulsion polymers as well as to their use in hair care preparations such as in particular in hair styling preparations. | 2013-12-26 |
20130344020 | HAIR STYLING COMPOSITION - A hair treatment composition comprising: i) a polyacrylate cross polymer; and ii) an acrylic pressure sensitive adhesive comprising: a) an acrylic group having a side-chain with at least 4 carbons (eg n-butyl acrylate or 2-ethylhexyl acrylate) and; b) a short side-chain acrylic such as methyl acrylate. | 2013-12-26 |
20130344021 | Cosmetic Or Pharmaceutical Composition Comprising Modified Polyorganosiloxanes - Cosmetic or pharmaceutical compositions comprising one or more substituted aminopolyorganosiloxanes (S | 2013-12-26 |
20130344022 | HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME - The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions. | 2013-12-26 |
20130344023 | POLYMER-ACTIVE AGENT CONJUGATES - A polymer includes at least one monomeric unit represented by Formula I, II, or III: where X is CH | 2013-12-26 |
20130344024 | Co-Therapy for Diabetic Conditions - Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed. | 2013-12-26 |
20130344025 | METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY - The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family is selected among Fas ligand, CD40L, TRAIL and APRIL. | 2013-12-26 |
20130344026 | Dimeric Smac Mimetics - The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 2013-12-26 |
20130344027 | MULTI-FUNCTIONAL POLYMERIC MATERIALS AND THEIR USES - Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject. | 2013-12-26 |
20130344028 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 2013-12-26 |
20130344029 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2013-12-26 |
20130344030 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2013-12-26 |
20130344031 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS - Compounds represented by formula (Ia) or (Ib) and wherein R and R | 2013-12-26 |
20130344032 | Method of Treating Anemia Caused By Ribavirin Treatment of Hepatitis C Using Erythropoietin Alpha - Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy, renal failure and HIV. It has not been used for anemia caused by ribavirin. Ribavirin is part of a two-drug regimen now used to treat hepatitis C along with alpha interferon. The principal side effect of ribavirin is a hemolytic anemia. In the past, management of that anemia was done by dose reduction of the ribavirin, sometimes resulting in reversal of part of the anemia. It has become particularly important in light of new data, to maximize the dose of ribavirin given to persons undergoing treatment for hepatitis C to ensure a successful eradication of hepatitis C. | 2013-12-26 |
20130344033 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) - The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof. | 2013-12-26 |
20130344034 | Parovirus Having a CpG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma. | 2013-12-26 |
20130344035 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS - Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit. | 2013-12-26 |
20130344036 | PLANT DERIVED CELL CULTURE MATERIAL - The present invention relates material that is useful in culturing and transferring cells as well as delivering cells. The material comprises plant derived cellulose nanofibers or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof. | 2013-12-26 |
20130344037 | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 2013-12-26 |
20130344038 | METHOD FOR ENHANCING ENGRAFTMENT OF HAEMATOPOETIC STEM CELLS - The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analogue for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided. | 2013-12-26 |
20130344039 | TH1-ASSOCIATED MICRORNAS AND THEIR USE FOR TUMOR IMMUNOTHERAPY - Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. | 2013-12-26 |
20130344040 | PROCESS FOR THE PREPARATION OF A COMPOSITION OF GENETICALLY MODIFIED HEMATOPOIETIC PROGENITOR CELLS - Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection. | 2013-12-26 |
20130344041 | GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS - An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed. | 2013-12-26 |